{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:47:30Z","timestamp":1792406850919,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its characteristic and prognosis value in hormonal sensitive prostate cancer is unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We aimed to evaluate the prognostic role of AR-V7 by progression free survival (PFS) and overall survival (OS) in hormonal sensitive prostate cancer (HSPC), and the AR-V7-positive-proportion difference in HSPC and CRPC. A search of PubMed, Embase, and the Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma; AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Seventeen trials published due December 2019 were enrolled.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>AR-V7-positive proportion in CRPC was significantly larger than newly diagnosed prostate cancer (PCa) (odds ratio [OR] 7.06, 95% confidence interval [CI] 2.52\u201319.83, P\u2009&lt;\u20090.001). Subgroup analyses indicated significantly higher AR-V7-positive proportion in CRPC derived from RNA in situ hybridization (OR 65.23, 95% CI 1.34\u20133171.43, P\u2009=\u20090.04), exosome RNA (OR 3.88, 95% CI 0.98\u201315.39, P\u2009=\u20090.05) and tissue RNA (OR 10.89, 95% CI 4.13\u201328.73, P\u2009&lt;\u20090.001). AR-V7-positive patients had a significantly shorter PFS than those who were AR-V7-negative treated with first-line hormonal therapy (hazard ratio [HR] 3.63, 95% CI 1.85\u20137.10, P\u2009&lt;\u20090.001) and prostatectomy (HR 2.49, 95% CI 1.33\u20134.64, P\u2009=\u20090.004). OS (HR 5.59, 95% CI 2.89\u201310.80, P\u2009&lt;\u20090.001) were better in AR-V7-negative than AR-V7-positive HSPC patients treated with first-line hormonal therapy. The limitations of our meta-analysis were differences in study sample size and design, AR-V7 detection assay, and disease characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AR-V7-positive proportion was significantly higher in CRPC than that in newly diagnosed PCa. AR-V7 positive HSPC patients portend worse prognosis of first-line hormonal therapy and prostatectomy. Additional studies are warranted to confirm these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-020-01229-4","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T11:03:42Z","timestamp":1588763022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4985-0877","authenticated-orcid":false,"given":"Zhize","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"issue":"2","key":"1229_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1229_CR2","doi-asserted-by":"crossref","unstructured":"Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA: a cancer journal for clinicians 2002, 52(3):154-179.","DOI":"10.3322\/canjclin.52.3.154"},{"issue":"6","key":"1229_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","volume":"16","author":"G Attard","year":"2009","unstructured":"Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 2009;16(6):458\u201362.","journal-title":"Cancer Cell"},{"issue":"4","key":"1229_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","volume":"8","author":"Y Chen","year":"2008","unstructured":"Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440\u20138.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"1229_CR5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305\u201313.","journal-title":"Cancer Res"},{"issue":"1","key":"1229_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16\u201322.","journal-title":"Cancer Res"},{"issue":"13","key":"1229_CR7","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469\u201377.","journal-title":"Cancer Res"},{"issue":"11","key":"1229_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Eng J Med. 2014;371(11):1028\u201338.","journal-title":"N Eng J Med"},{"issue":"5","key":"1229_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582\u201391.","journal-title":"JAMA Oncol"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35:2149.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1229_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","volume":"68","author":"W Onstenk","year":"2015","unstructured":"Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. 2015;68(6):939\u201345.","journal-title":"Eur Urol"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2019.08.020","volume":"77","author":"RP Graf","year":"2019","unstructured":"Graf RP, Hullings M, Barnett ES, Carbone E, Dittamore R, Scher HI. Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer. Eur Urol. 2019;77:170.","journal-title":"Eur Urol"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.euf.2017.01.004","volume":"4","author":"H Li","year":"2017","unstructured":"Li H, Wang Z, Tang K, Zhou H, Liu H, Yan L, Guan W, Chen K, Xu H, Ye Z. Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis. Eur Urol Focus. 2017;4:529.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1229_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/modpathol.2017.74","volume":"31","author":"H Li","year":"2018","unstructured":"Li H, Wang Z, Xiao W, Yan L, Guan W, Hu Z, Wu L, Huang Q, Wang J, Xu H, et al. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Mod Pathol. 2018;31(1):198\u2013208.","journal-title":"Mod Pathol"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"7654","DOI":"10.1038\/srep07654","volume":"5","author":"Y Qu","year":"2015","unstructured":"Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015;5:7654.","journal-title":"Sci Rep"},{"issue":"7","key":"1229_CR16","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.","journal-title":"PLoS Med"},{"issue":"3","key":"1229_CR17","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365\u201380.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1229_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76\u201385.","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"1229_CR19","doi-asserted-by":"publisher","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E Hornberg","year":"2011","unstructured":"Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE. 2011;6(4):e19059.","journal-title":"PLoS ONE"},{"issue":"24","key":"1229_CR20","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00018-011-0766-7","volume":"68","author":"S Haile","year":"2011","unstructured":"Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci. 2011;68(24):3971\u201381.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"1229_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.eururo.2017.08.009","volume":"73","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, et al. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur Urol. 2018;73(5):727\u201335.","journal-title":"Eur Urol"},{"issue":"2","key":"1229_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/1078-0432.CCR-16-0237","volume":"23","author":"PJ Saylor","year":"2017","unstructured":"Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, et al. Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2017;23(2):363\u20139.","journal-title":"Clin Cancer Res"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41416-018-0172-0","volume":"119","author":"HML Kallio","year":"2018","unstructured":"Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, et al. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119:347.","journal-title":"Br J Cancer"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","volume":"70","author":"J Welti","year":"2016","unstructured":"Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:599.","journal-title":"Eur Urol."},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1229_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cells8070688","volume":"8","author":"M Nimir","year":"2019","unstructured":"Nimir M, Ma Y, Jeffreys SA, Opperman T, Young F, Khan T, Ding P, Chua W, Balakrishnar B, Cooper A, et al. Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor rna and exosomes. Cells. 2019;8(7):688.","journal-title":"Cells"},{"issue":"9","key":"1229_CR27","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","volume":"26","author":"M Nakazawa","year":"2015","unstructured":"Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals Oncol. 2015;26(9):1859\u201365.","journal-title":"Annals Oncol"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/RRU.S98877","volume":"8","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Okuno Y, Hattori-Kato M, Zaitsu M, Mikami K. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Reports Urol. 2016;8:21\u20135.","journal-title":"Res Reports Urol"},{"issue":"1","key":"1229_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1039\/C8LC01185K","volume":"19","author":"HK Woo","year":"2018","unstructured":"Woo HK, Park J, Ku JY, Lee CH, Sunkara V, Ha HK, Cho YK. Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. Lab Chip. 2018;19(1):87\u201397.","journal-title":"Lab Chip"},{"issue":"1","key":"1229_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/pros.23248","volume":"77","author":"CH Lee","year":"2017","unstructured":"Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK. Transcript levels of androgen receptor variant 7 and ubiquitin-conjugating enzyme 2C in hormone sensitive prostate cancer and castration-resistant prostate cancer. Prostate. 2017;77(1):60\u201371.","journal-title":"Prostate"},{"key":"1229_CR31","first-page":"1","volume":"5","author":"HK Park","year":"2019","unstructured":"Park HK, Lim SD, Kwon GY. mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer. Scand J Urol. 2019;5:1\u20137.","journal-title":"Scand J Urol"},{"issue":"11","key":"1229_CR32","doi-asserted-by":"publisher","first-page":"e27970","DOI":"10.1371\/journal.pone.0027970","volume":"6","author":"X Zhang","year":"2011","unstructured":"Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE. 2011;6(11):e27970.","journal-title":"PLoS ONE"},{"issue":"4","key":"1229_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4103\/1008-682X.178490","volume":"18","author":"J Luo","year":"2016","unstructured":"Luo J. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian J Androl. 2016;18(4):580.","journal-title":"Asian J Androl"},{"issue":"5","key":"1229_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2017.11.038","volume":"73","author":"J Luo","year":"2018","unstructured":"Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, et al. Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting. Eur Urol. 2018;73(5):715\u201323.","journal-title":"Eur Urol"},{"issue":"2","key":"1229_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256\u201362.","journal-title":"Eur Urol"},{"issue":"10024","key":"1229_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377.","journal-title":"Lancet"},{"issue":"2","key":"1229_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149\u201358.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1229_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Eng J Med. 2015;373(8):737\u201346.","journal-title":"N Eng J Med"},{"issue":"4","key":"1229_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","volume":"73","author":"V Cucchiara","year":"2018","unstructured":"Cucchiara V, Cooperberg MR, Dall\u2019Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572\u201382.","journal-title":"Eur Urol"},{"issue":"1","key":"1229_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","volume":"129","author":"A Sharp","year":"2019","unstructured":"Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Investig. 2019;129(1):192\u2013208.","journal-title":"J Clin Investig"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-020-01229-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:11:39Z","timestamp":1620259899000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-01229-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-01229-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"7 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}